Table 1.

Summary of findings of studies investigating the influence of immunosuppressive treatment on humoral vaccine responses in children and adolescents with JARD in comparison to control children (results from last follow-up time-point of each study)

	HAV	HBV	HPV	Diphtheria	Tetanus	Influenza A/H1N1	Influenza A/H3N2	Influenza B	MenC	Pneumococcus	Measles	Mumps	Rubella	Varicella
Enthesitis-related arthritis
GMT											↓43		↓43
SPR											= 43		= 43
Juvenile dermatomyositis
GMT						= 23
SPR			= 42			= 23
SCR						↓23
Juvenile idiopathic arthritis
GMT	↓13	↓16	= 44	↓30	↓30	↑28 ↓31  = 12,22,29	↓28  = 12,29,31	↓28,31  = 12,29	↓26  = 20	↓38  = 19	↑30,45 ↓14*  = 14°	↑45 ↓30  = 14	↑45 ↓30  = 14
SPR	↓35  = 13	↓16		↓30	↓30	= 12,22,29,31,46	↑46  = 12,29,31	↓31,46  = 12,29		= 19,38	↑30‡  = 30†	↓30†  = 30‡	↓30†  = 30‡
SCR	= 13					↓22,28,46  = 12,29,31	↑46 ↓28  = 12,29,31	↑46 ↓28,31  = 12,29		= 19
Systemic lupus erythematosus
GMT		↓34			↓36§  = 15,36¶	↓21					= 36			= 47
SPR		= 34				↓21
SCR						↓21
Juvenile autoimmune rheumatic disease
GMT			= 48		↓40	↓32  = 18,33,37	= 33,37	↑37  = 33			= 40		= 40	= 24,25,39
SPR						↓32  = 18,33	= 33	= 33						= 39
SCR						↓32  = 18,33,37	= 33,37	= 33,37

GMT geometric mean titre, HAV hepatitis A virus, HBV hepatitis B virus, HPV human papillomavirus, MenC meningococcus C, SCR seroconversion rate, SPR seroprotection rate

^¶Active systemic lupus erythematosus

^§Inactive systemic lupus erythematosus

°Methotrexate ± etanercept > 4 years after mumps - measles rubella vaccination

^‡One dose of monovalent measles vaccine followed by measles-mumps-rubella vaccination

^†Two doses of measles-mumps-rubella vaccination